Skip to content
Ransomware

Summit Veterinary Pharmaceuticals Limited targeted by raworld ransomware group

The raworld ransomware group has listed 60GB of data allegedly belonging to SUMMIT VETERINARY PHARMACEUTICALS LIMITED on their leak site.

By
Siberpol Intelligence Unit
Published
3 min read
3 min read
  • Ransomware group: raworld
  • Country: United Kingdom
  • Sector: Healthcare
  • Announcement date: March 21, 2024

A major data breach claim against Summit Veterinary Pharmaceuticals Limited

The threat actor known as raworld has listed SUMMIT VETERINARY PHARMACEUTICALS LIMITED on its leak site, claiming to have successfully executed a cyberattack against the organization. According to the announcement made on March 21, 2024, the group alleges they have obtained a significant volume of sensitive information belonging to the company.

This incident follows a common pattern observed in modern cybercrime, specifically involving ransomware groups that utilize leak sites to pressure victims. In such scenarios, threat actors often employ a tactic known as double extortion. This method involves not only encrypting an organization's internal systems to disrupt operations but also exfiltrating sensitive data to use as leverage. By threatening to publish this stolen information on a public platform, the attackers aim to increase the likelihood of receiving a ransom payment through the threat of reputational damage and regulatory scrutiny.

Details of the alleged data theft

The raworld ransomware group claims to have exfiltrated approximately 60GB of data from the victim. While the group has not provided specific details regarding their methods or the exact nature of the breach, the volume of data suggests a broad intrusion into the organization's digital infrastructure. Publicly available information regarding the specific tactics, techniques, and procedures (TTPs) used by this particular group remains limited.

The data allegedly stolen by the attackers is extensive and covers multiple critical business functions. The content reportedly includes a wide variety of sensitive files that could impact both the company's operations and the privacy of its personnel. The alleged stolen data includes:

  • Daily order scans
  • Purchase orders
  • Inventory reports
  • Production documentation
  • BMR and BPR records
  • New product information
  • Human resources files
  • Personnel records
  • Development documents
  • Staff folders
  • Financial data
  • Shipping information

About Summit Veterinary Pharmaceuticals Limited

Summit Veterinary Pharmaceuticals Limited is a company based in the United Kingdom. The organization specializes in the development and manufacture of specialized medications and pharmaceutical solutions specifically designed for veterinarians. Given its role in the healthcare sector, the company handles sensitive information related to pharmaceutical production, supply chains, and regulatory compliance.

Potential risks and implications of the breach

The alleged leak of this data poses several significant risks to the organization. Because the stolen information reportedly contains operational and financial data, as well as sensitive information regarding employees, the impact could be multifaceted. For a UK-based organization, a confirmed breach of this nature could trigger serious legal obligations and potential sanctions under the UK GDPR (General Data Protection Regulation), which governs how personal data must be protected and reported.

The exposure of human resources and financial data introduces secondary risks, such as the potential for identity theft or highly targeted phishing attacks directed at the organization's employees. Furthermore, the disclosure of production and development documents could jeopardize the company's trade secrets and erode its competitive advantage in the pharmaceutical market. The specific details of the threat's scope remain difficult to assess due to the limited information available about the group's motivations and methods.

In general, organizations within the healthcare and pharmaceutical sectors can mitigate such risks by implementing robust security frameworks. Common defensive steps include maintaining strict access controls, implementing multi-factor authentication (MFA), and ensuring comprehensive encryption for data at rest and in transit. Regular security audits, employee training to recognize phishing attempts, and maintaining offline, immutable backups are also essential components of a resilient cybersecurity posture designed to defend against ransomware and data exfiltration.

From the Essential plan

Third-Party Risk

Monitor leaks on your suppliers’ domains and identify at-risk suppliers at an early stage.

Related stories